CardioVascular BioTherapeutics, ProDerm L.P. deal

CardioVascular will receive $1-$10 million from ProDerm to fund future clinical trials of CVBT-141B to treat diabetic foot ulcers and venous stasis leg wounds. In return, ProDerm is eligible for 10% ...